Immune and inflammatory mediator pathways

Immune and inflammatory mediator pathways encompass the complex signaling networks, such as the NF-κB and JAK-STAT cascades, that coordinate the host response to infection and tissue injury (Medzhitov, R., Nature, 2008). These pathways involve a diverse array of molecular components, including pro-inflammatory cytokines like TNF-α, IL-1, and IL-6, which act as primary drivers of the inflammatory response (Dinarello, C. A., Blood, 2011). While these processes are vital for host defense, their chronic dysregulation is central to the pathogenesis of autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease (Nathan, C., Nature, 2002). Therapeutic strategies often involve the use of monoclonal antibodies or small molecule inhibitors to target specific nodes within these pathways, such as TNF inhibitors or JAK inhibitors (O'Shea, J. J., et al., Immunity, 2013). However, because these pathways are fundamental to immune surveillance, pharmacological intervention carries significant risks, most notably an increased susceptibility to serious and opportunistic infections. Consequently, drug development in this space requires a careful balance between efficacy in dampening inflammation and maintaining sufficient immune competence.

Other names

Inflammatory signaling pathwaysImmune response pathwaysCytokine signaling cascadesInflammatory mediator signaling

Modulation of signaling cascades (e.g., JAK-STAT, NF-κB) or neutralization of specific ligands (e.g., TNF, IL-6) to regulate inflammatory gene expression and cellular activity.